A number of studies have examined the impact of tumor stage on direct health care costs of patients with melanoma. This study aimed to investigate the association between the direct costs for melanoma
Mean incremental costs (in US dollars) per treatment episode—AEs of any severity, stratified by common tumor type (≥6% of selected patients). Each n indicates the number of treatment episodes.
aThe US$ values in the parenthesis represent negative values, it means that all parameters were cost saving.Sensitivity analysis of the relevant parameters of the incremental cost of the bevacizumab-a
